Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661952 | 1.00 | F2RL1 (0.32) | F2RL1MAPTDGAT1ATRATRIP | |
| SCHEMBL29966986 | 0.82 | DGAT1 (0.35) | F2RL1MAPTDGAT1ATRATRIP | |
| SCHEMBL30720732 | 0.81 | DGAT1 (0.37) | F2RL1MAPTDGAT1ATRATRIP | |
| SCHEMBL15667485 | 0.81 | MAPT (0.35) | F2RL1MAPTDGAT1ATRATRIP | |
| SCHEMBL29662049 | 0.81 | MAPT (0.35) | F2RL1MAPTDGAT1ATRATRIP | |
| SCHEMBL25049222 | 0.81 | DGAT1 (0.33) | F2RL1DGAT1ATRATRIP | |
| SCHEMBL30595148 | 0.80 | MAPT (0.34) | F2RL1MAPTDGAT1ATRATRIP | |
| SCHEMBL20745940 | 0.80 | MAPT (0.34) | F2RL1MAPTDGAT1ATRATRIP | |
| SCHEMBL20746046 | 0.79 | MAPT (0.34) | F2RL1MAPTDGAT1ATRATRIP | |
| SCHEMBL19780125 | 0.78 | DGAT1 (0.32) | F2RL1MAPTDGAT1ATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2021003161-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | F2RL1 1354/4885MAPT 2805/4885DGAT1 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.